Reactions of the multiply bonded dirhenium complexes [Re₂X₄(L–L)₂]ⁿ⁺(X = Cl or Br, L–L = Ph₂PCH₂CH₂PPh₂or Ph₂PCH₂CH₂AsPh₂; n= 0 or 1) with isocyanides and nitriles. Reaction without metal–metal bond disruption

Solid state NMR and X-ray diffraction studies of α-d-galacturonic acid monohydrate

“…Computer programs used in this analysis have been noted above or in Table 4 of Ref. 30, and were run on a DEC-AlphaStation 200 4/100 in the Nitrogen Fixation Laboratory at the John Innes Centre.…”

Bioinformatics Tools and Workflow to Select Blood Biomarkers for Early Cancer Diagnosis: An Application to Pancreatic Cancer

“…Indeed, this subgroup may be of particular interest as the cleavage and release of membrane proteins have been reported to be indicative of early cancer development. [2,15,23] Because secreted and cell-surface proteins are likely to end up in the systemic blood circulation and thus be detectable in the plasma/serum, they represent biomarkers with a high value for early cancer diagnosis. Information relating to the subcellular localization of candidates in our list was obtained from the neXtProt database, which is built on a corpus containing both curated knowledge originating from the UniProtKB/Swiss-Prot knowledgebase and carefully selected and filtered high-throughput data relevant to human proteins.…”

“…To be useful, a biomarker must be a measurable component compatible with routine detection in clinical practice. [2] Moreover, an effective biomarker should be sufficiently sensitive and specific to distinguish solid tumors from other pathological conditions. [3] Examples of plasma/serum cancer biomarkers that are routinely used in clinical oncology for cancer diagnosis include prostate specific antigen (PSA) for prostate cancer [4] and carcinoembryonic antigen (CEA) for colorectal cancer.…”

Label‐Free Quantitative Proteomic Screening of Candidate Plasma Biomarkers for the Prognosis of Breast Cancer with Different Lymph Node Statuses

“…In plasma or serum, more than 100 protein biomarkers have been approved by the Food and Drug Administration (FDA). [9] Over the past decades, proteomic techniques based on MS are fast-developing and have been successfully applied in clinic for disease diagnosis. For example, the first proteomic diagnostic test approved by FDA, the OVA1 test based on surface-enhanced laser desorption/ionization-TOF-MS, has greatly improved the sensitivity and specificity of the diagnosis of ovarian cancer.…”